We describe an infant with juvenile chronic myelogenous leukemia (JCML), the diagnosis of which was made by the characteristic clinical and hematologic findings. The absence of a related HLA - compatible donor for bone marrow transplantation coupled with the awareness that chemotherapy is usually ineffective prompted our decision to treat the patient with lymphoblastoid interferon-α [αLy)-IFN]. During the 26-month course of treatment with αLy)-IFN an incomplete regression of hematologic and clinical findings was achieved. The above results, along with the easy administration and absence of considerable side effects, suggest that αLy)-IFN may be a useful therapeutic tool in patients affected by JCML awaiting bone marrow transplantation.
- Juvenile chronic myelogenous leukemia
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Cancer Research
- Management of Technology and Innovation